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REMINISCENCES: 
MY FORTY-YEAR ROMANCE WITH MALARIA 
G. Robert Coatney 
5012 Wickford Way, NE 
Dunwoody, Georgia 30338 
Prologue 
Looking back some 55 years since beginning my graduate 
studies, I have come to appreciate my good fortune: (1) to 
have inaugurated and carried out, over a period of some 35 
years, a three-pronged research program (birds, simians, and 
man) against the world's most important infectious disease-
malaria -and during two-thirds of that time, carrying worri-
some administrative responsibilities; (2) to have participated 
in national and international efforts towards alleviation and 
control of that disease; (3) to have had a remarkable group 
of professional and subprofessional people who shared all 
kinds of problems; (4) to have received full support of my 
scientific efforts from the Directors of the National Institutes 
of Health, and last, but not least; (5) to have a wife who ac-
cepted my sometimes extended peregrinations, here and 
abroad, necessitated by my commitment to the problem of 
malaria. A reporter might ask, "How did a native Nebraskan, 
brought up with winter's snow and hot dry summers choose a 
tropical disease career?" 
t t t 
After receIvmg the B.A. degree from the Grand Island 
Baptist College, an M.A. from the University of Nebraska, and 
a teaching interlude, I contacted Dr. E. R. Becker of Iowa 
State University about studying with him for the Ph.D. He 
invited me to visit him and during our conversation he asked 
me if I had a problem in mind or if he should select one. I 
wanted to work on blood protozoa and suggested studying the 
relapse phenomenon in Haemoproteus columbae, sometimes 
referred to as pigeon malaria. He approved the problem, and 
I won the degree. 
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Armed with this new parchment, I learned of an opening 
in the biology department at Nebraska Wesleyan University. 
After a conference with Dr. Claude Shirk, chairman of the 
department, I was offered the position and went there as an 
associate professor. My teaching duties were less than arduous; 
research was encouraged. In that atmosphere I expected to 
continue for an extended period. However, the depression 
which struck the midwest in 1932 soon saw the university in 
financial straits augmented by the failure of the Peters Trust 
Company in Omaha, where most of the university's endow-
ment funds were on deposit. Our salaries were reduced by one 
half and for a period of five months we received no money. 
Luckily, a position opened at the Peru State Teachers Col-
lege for which I applied and was hired. The college was estab-
lished to train teachers for the Nebraska schools-hardly an 
atmosphere for a research-minded associate professor of biol-
ogy. As it turned out, there were compensations. 
My studies involving H. columbae had whetted my inter-
est in true malaria. At that time there was a broad interest in 
avian malarias but in-depth studies were limited to infections 
in the canary, which carried only a small amount of blood. 
This could be overcome with a malaria in a larger bird. Peru 
was located in a major flyway, and non-migratory birds were 
all about. One of them might be carrying a true malaria that 
would grow well in a larger bird attuned to laboratory condi-
tions-a chicken or the common pigeon. I decided to study 
the bird parasites of that bird population with one object 
only: to find that parasite! 
During the next four years I described and named some 
15 new species of protozoan blood parasites, but the prize was 
missing-no true malaria. Owls, crows, magpies, and other 
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birds, carrying protozoan blood parasites, were kept caged in 
the laboratory and, as a sideline, so to speak, their infections 
were treated using the then available antimalarial drugs. These 
initial studies in chemotherapy were reported in several short 
papers, but I attached no particular significance to them. As it 
turned out, those preliminary studies pointed the way for my 
subsequent career. 
Among the male members of the Peru faculty I was an 
oddity. I didn't play golf, I didn't hunt, and I didn't follow the 
fate of the athletic teams. All I did was teach, roam the woods, 
and work in the laboratory. According to my lights, the elu-
sive malaria parasite would not be found on the golf course. 
Mourning doves nested on the campus and each summer 
no malaria parasites were found in their blood. In 1937, how-
ever, a nestling was found with a true malaria. It was identified 
as Plasmodium relictum With that "find" the paramount ques-
tion was: would it grow in the chicken, other doves, or in the 
pigeon? Before those questions could be answered, the same 
species was found in a young pigeon taken from a nest under 
the wheel-house of the college observatory. Were they the 
same parasite? They were, as determined by cross infection 
experiments. In the pigeon the parasite produced a fulminating 
infection, even death. I had found the long-sought malaria 
parasite! 
I reported finding this "new" parasite at the fall meeting 
of the American Society of Parasitologists, was congratulated 
on my good fortune, and had numerous requests to share the 
parasite with other investigators. I was not anxious to do so 
until I had time to study it myself. This reluctance was under-
stood by other investigators. 
In early 1938, I received a letter from Dr. L. L. Williams, 
in charge of malaria research for the U.S. Public Health Serv-
ice, asking me if I would share my new parasite for extended 
studies by the Public Health Service. It took me less than five 
seconds to make up my mind about that. In my reply, I told 
Dr. Williams that I had spent almost five years in search of that 
parasite and if the Public Health Service wanted it they could 
have it but they would have to take me too. If the ploy 
worked I would be in full-time research. 
After a series of negotiations and an interview in Wash-
ington, D.C., I was offered an appointment to the research 
staff of the Williams Malaria Research Laboratory located at 
the South Carolina State Hospital in Columbia. The malaria-
infected pigeons and the Coatney family, which now included 
our four-year-old daughter, moved to Columbia. 
When I reported for work there I met Dr. Martin Young 
who, I learned later, had called Dr. Williams's attention to the 
new pigeon malaria. Martin was engaged in studies dealing with 
the biology and mosquito transmission of human malarias, 
especially vivax and malariae, used by the medical staff for 
treating central nervous system syphilis Oues nervosa). My 
pigeon malaria studies moved ahead, but I lost no time in join-
ing Martin in cooperative studies dealing with the human 
malarias. 
Early in 1938 the Surgeon General of the Public Health 
Service (PHS) saw that war was imminent. If it came, Amer-
ican soldiers would have to fight in highly malarious areas of 
the world, and quinine was the only drug then available for 
its treatment. In order to try and improve that situation, he 
initiated a program at the National Institutes of Health (NIH), ' 
under the direction of Dr. Lyndon Small, for the synthesis of 
potential antimalarial compounds. These new compounds 
would have to be tested initially against malarias in lower 
animals. That part of the program called for someone with 
drug-testing experience. A survey of the PHS personnel found 
only one person with such experience-myself. As a result, I 
was transferred to the NIH to set up such a program. That 
move brought the family, which now included our two-year-
old son, into the Washington, D.C., area which was our home 
for the next 25 years. 
The Department of Agriculture, for obvious reasons, had 
barred the importation of Plasmodium gallinaceum, a malaria 
parasite of chickens, but now, with war on the horizon, they 
relented. As a consequence, I chose to use day-old chicks and 
the gallinaceum parasite in evaluating new potential drugs. 
The chemists had several compounds ready for testing, but my 
procedure for their evaluation failed to satisfy a certain medi-
cal officer, who had control of the program. I am sure he was 
qualified as a physician but, in my opinion, he was not a quali-
fied experimental scientist. I refused to modify the program 
and notified the director that I was ready to go back to South 
Carolina. The impasse was settled by my being given sole 
responsibility for the testing program. 
Under an increased staff, a goodly number of compounds 
were tested, none of which showed promise, until we tested 
NIH 204, a phenanthrene amino alcohol. It was vastly superior 
to quinine against P. gallinaceum in the chicks, but would it 
work in man? The answer might be found at the St. Eliza-
beth's Hospital in Washington, D.C. The physicians there used 
vivax malaria in treating luetics. When their patient had ex-
perienced the required treatment, the disease was terminated 
with quinine. Why not test the effectiveness of our new drugs, 
like NIH 204, in terminating those infections? If the trial drug 
reduced or terminated the infection, we would have a lead, Of 
a new drug, for further tests. I could see no difficulty in PHS 
physicians working with physicians at St. Elizabeth's Hospital. 
The problem was that my staff did not include a physician. 
Where was I to get one with a flair for research to evaluate, 
NIH 204 or other test drugs? I appealed to Dr. Henry Sebrell, 
my institute chief, for help. A few days later he told me about 
a young M.D. who wanted to join the PHS but was then work-
ing for a master's degree in bacteriology at Johns Hopkins Uni-
versity. I went over his Curriculum Vitae and immediately 
asked that he be assigned to me at the NIH. Dr. Clark Cooper 
joined my staff on 13 December 1941, six days after Pearl 
Harbor. We worked as a team for the next eight years. 
Arrangements were made quickly with the St. Elizabeth's 
staff, and Cooper took over the testing of NIH 204. It proved 
to be an excellent drug, but certain side effects prevented its 
general use. He then tested a whole series of compounds of 
similar structure, but each of them exhibited the same limita-
tions. It was obvious that we would have to move in a differ-
ent chemical direction. 
A National Malaria Program had been organized by the 
Committee on Medical Research under the Office of Scientific 
Research and Development and its activities, on a nationwide 
basis, had progressed to where test compounds were coming to 
us from other laboratories. The testing of those compounds, as 
well as our own, soon exhausted the supply of available mental 
hospital patients. With that avenue cut off, another source of 
human test subjects had to be found. 
Cooper and I were discussing this sorry state of affairs in 
my office one afternoon when we were joined by Dr. David 
Ruhe who had recently joined our staff. Dave listened to the 
discussion for a time and then said, "Chief, have you ever 
thought of using prisoner volunteers?" I was struck by the idea 
and decided to investigate the possibility at once. 
The PHS supplies physicians for the Federal Prison Serv-
ice and Dr. Marion King was the Medical Director. My course 
of action was-go to your friends first. I went to see Dr. King 
the very next morning and explained the situation to him. 
There was a war on and a pressing need for new and better 
drugs for the treatment of malaria. Could it be arranged so 
that potentially effective drugs could be tested in prisoner 
volunteers? Dr. King knew and approved of our work but 
made it clear that using malaria for treating lues in mental 
patients was an acceptable practice; employing prison volun-
teers for testing new drugs was quite another matter. I fully 
appreciated his position. He was being asked to approve a pro-
gram contrary to accepted medical practice. After a time he 
agreed to endorse the program but made it clear that final 
approval rested with the director, James V. Bennett. Fortu-
nately, the director's daughter was one of my technicians, and 
I hoped that might contribute to a favorable decision. When 
we saw Mr. Bennet I laid the problem before him stressing the 
fact that after Pearl Harbor the Japanese had cut off our 
quinine supply, our stockpile was low, and the United States 
needed effective new drugs for the treatment of malaria. He 
listened carefully and after some time he turned to Dr. King 
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and said, "Marion, what do you think of the idea?" His reply 
was that "If Dr. Coatney is to be in charge, I'm for it." Mr. 
Bennett then wanted to consider the best place for the project. 
I suggested the prison in Atlanta, Georgia, because it was close 
to Milledgeville, Georgia, and to Columbia, South Carolina, 
where Drs. Geoffrey Jeffery and Martin Young of the PHS 
could easily supply infected mosquitoes for the project. Also, 
Atlanta was easy for me to get to from Washington, and the 
prison population should supply ample volunteers. Mr. Bennett 
was quick to point out that Atlanta was hardly a minimum 
security prison. He finally agreed that Atlanta was the best 
place under the circumstances and to make our work easier he 
called Mr. Sanford, the warden at Atlanta Prison, and told him 
that he had approved a project which Dr. King and I would 
present to him in a day or two. 
Dr. King and I went to Atlanta and found Mr. Sanford far 
from pleased with the proposed drug-testing project. He had a 
contract for making mattresses for the army and mail bags for 
the post office which yielded Prison Industries about $2 million 
per year. In his light, he had reason to see us gone. I pointed 
out to the warden that there was a war on and that $2 million 
was a mere pittance in terms of the war effort and the crying 
need for better antimalarial drugs. He finally agreed and in-
vited me to return in a few days to present the project to the 
inmate popUlation. When I next visited Atlanta, I took Dr. 
Ruhe with me. The warden brought the men together in the 
Great Hall of the prison with its catwalk near the ceiling and 
guards with rifles. It goes without saying that I was not exactly 
calm and collected under those conditions. The warden gave a 
short talk and then turned the meeting over to me. I explained 
the need for new antimalarial drugs for the armed forces and 
the need for volunteers in assessing the effectiveness of the 
new drugs. 
I made it doubly clear that participants would have to be 
of military age; in excellent physical condition; be willing to 
accept infection with malaria, either by mosquito bite or by 
blood in inoculation; and to accept medication and routine 
tests as required. Each volunteer would have to agree to stay 
with the project for a period of six months. At the end of that 
period he would receive an honorarium of $50 (later raised to 
$250) and six months would be taken off his sentence. In 
addition, he would receive an attractive certificate signed by 
the Surgeon General of the PHS and other dignitaries certify-
ing as to his participation in a research study with broad signif-
icance to mankind. I was careful to ~oint out that many of 
them would be sick and some so sick that they would wish 
they had never heard of us and the "drug-testing program. I 
went on to say that there was little likelihood of a fatal out-
come and that our physicians would take care of all their 
medical problems. 
With that coverage of the program, I invited those who 
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might like to take part in the program to meet me at the foot 
of the steps. I stepped down onto the floor and the men came 
forward like a wave. One fellow said to me, "Doc, did you say 
that all our medical problems would be handled by your 
doctors?" I replied that that was exactly what I had said and 
the man on his left, Dr. Ruhe, would do exactly that. The 
questioner turned to those behind him and said, "Boys, let's 
go." They were with us! I am proud to say that was the only 
time we asked for volunteers. Over the years the project spoke 
for itself in enlisting more than one thousand volunteers from 
that institution. 
With the support of the warden and the inmates, the way 
was cleared for remodeling the hospital to accommodate us 
and for enlisting a complete staff. It was not until St. Patrick's 
Day 1944 that the first 15 volunteers were infected with vivax 
malaria following the bites of infected mosquitoes. It was my 
privilege to take part in applying infected mosquitoes on that 
historic occasion. I say "historic" because not only was this the 
only country in the world where prisoner participation in such a 
study was permitted, encouraged, and sanctioned by law, but 
what makes it stand out even more is that it was only the sec-
ond time in the history of the United States that prisoner volun-
teers took part in solving an important medical problem. 
Let us turn back for a moment to the first of these volun-
teer studies. Alex St. Martin was shot in the left breast and 
stomach in 1823. Dr. William Beaumont, serving in the Mich-
igan Territory, dressed the wound which, due to adhesions, 
failed to heal properly, allowing access to the stomach. Alex 
was unable to work and became Beaumont's body servant. 
With Alex's permission, Dr. Beaumont began the earliest 
extended studies of the physiology of digestion in 1825. The 
idea of participation in medical problems then lay fallow until 
1915, a span of 90 years, when Dr. Joseph Goldberger, a PHS 
medical officer working in Mississippi, employed 11 prisoner 
volunteers in solving the cause of pellagra, at that time the 
scourge of the south. The volunteers who participated in that 
important study were promptly released from prison, but their 
contribution was forgotten. The governor was berated by the 
public and the Mississippi medical profession for allowing their 
participation. Goldberger went on to receive many honors, but 
his landmark was pellagra. Again, the idea of prisoner volun-
teer participation in solving a medical problem lay fallow, this 
time for 29 years, to be broken on 17 March 1944 as men-
tioned earlier. 
We have not forgotten the outstanding results, to be de-
lineated later, of the volunteer studies begun in 1944, but we 
seem to have forgotten that it was prisoner volunteers who 
made the results possible. At this writing, prisoners in the 
United States are not permitted to participate in studies aimed 
at solving medical problems, suits in our courts to the contrary 
notwithstanding. But now back to the main theme. 
The effectiveness of test compounds was measured in 
terms of their quinine equivalent against St. Elizabeth's vivax 
malaria. As a consequence our initial work included intensive 
studies of the biology of the parasite and the effectiveness of 
quinine against it. With that basic information, evaluation of 
several groups of drugs, including a series of 4-aminoquinolines, 
got underway. Among that assemblage was SN-7618, now 
known as chloroquine, which proved to be an outstanding 
drug. It gave complete suppression of the disease, when taken 
once weekly, and was highly effective as a therapeutic agent. 
Unfortunately, it did not cure the underlying tissue infection. 
Chloroquine rapidly became the drug of choice the world over 
and still holds that position at this writing. 
By 1946, we had exhausted the supply of suitable patients 
at the Atlanta prison which made it necessary to move the 
project to the Federal Correctional Institution in Seagoville, 
Texas. At that facility studies were carried on to determine 
the effectiveness of pamaquine, isopentaquine, chlorguanide, 
and several antibiotics. 
In view of the favorable activity of chlorguanide,it seemed 
essential that we undertake assessment of chloloroquine and 
chlorguanide in the field. To implement that activity, a field 
unit from the Seagoville staff was set up in Guatemala in early 
1948. This study was made possible through a cooperative 
arrangement with that government, the PHS, and the Pan 
American Sanitary Bureau. All went well until the unsettled 
conditions in that country made it necessary to terminate the 
work. However, the results demonstrated clearly that each of 
the drugs reduced the incidence of malaria significantly; the 
greatest reduction occurred in areas under chloroquine sup-
pression. 
In 1949, those in "high places" decided that with the war 
over and an excellent drug in hand, malaria was of minor im-
portance. As a consequence, it was suggested that I might turn 
my energies to a more important problem-the common cold. 
I was not interested in the common cold and said so, knowing 
full well that as a commissioned officer I could be ordered to 
study it-I wasn't. 
The Seagoville installation was closed, and I decided to 
take a vacation. I had not had one since the war started except 
for six weeks in the hospital nursing a bleeding ulcer in 1946, 
if one can call that a vacation. We bought a new car, and the 
Coatney family took off for the West Coast on a two-month 
trip, hopefully without a telephone. All went well until while 
in Yellowstone Park, waiting for Old Faithful to erupt, the car 
radio was turned on and I learned that President Truman had 
sent troops into South Korea. 
It was plain that our vacation was about over because I 
could see that Commander Coatney would soon be back in 
prisoner volunteer ~alaria studies again. The life. pattern ~f 
Korean vivax malana was well known to me, WhICh made It 
obvious that many surgical cases flown to Walter Reed Hospi-
tal in Washington, D.C., would experience attacks of malaria 
about Christmas time. While those patients were in Korea they 
were on weekly doses of chloroquine, but when taken out of 
the area the drug would be withdrawn allowing the disease to 
express itself. What was needed was a curative drug. We had 
quit too soon! 
There had been a few trials of primaquine, a new 8-
amino qUinoline , by Dr. Alf Alving at the Statesville prison 
in Illinois which showed it to be four times as active and one-
fourth as toxic as pamaquine. There would have to be a more 
exhaustive evaluation of that drug before it could be recom-
mended to the armed services. In other words, the Atlanta 
operation would have to be reactivated, which involved hos-
pital space, a source of infected mosquitoes, and a new staff. I 
could handle all but one part of that setup, namely finding a 
capable physician with a research bent and willing to work 
behind bars. It would be unfair to ask Dr. Cooper to come 
back for he was then Chief of Medicine at the U.S. Public 
Health Hospital in San Francisco. However, in desperation I 
called him, mentioning that we were again at war and that I 
needed him. He came and stayed five months until Dr. Al 
Myatt was ready to take over. The primaquine studies in our 
volunteers showed that when employed at a dosage of 15 mg 
daily for 10 to 15 days, a regimen recommended by Dr. Leon 
Schmidt, it cured vivax infections. This was important infor-
mation but, in the absence of extensive toxicological data, it 
was deemed necessary to study the tolerability of the drug in 
soldiers rotated home from Korea. 
That study was carried out in 1951 involving a thousand 
army personnel at Fort Benning, Georgia, and at Fort Knox, 
Kentucky, under my supervision and Dr. Alving, respectively. 
Those tests demonstrated the overall safety of administering 
a single 15-mg dose of primaquine daily for 14 days to mili-
tary personnel on full duty. Following that demonstration an 
o;·der was issued stating that all soldiers returning from Korea 
by ship would be given 15 mg of primaquine daily for 14 days. 
That was done beginning in December 1951. The navy, on the 
other hand, had a shipload of marines ready to return to the 
States. The order said "soldiers" and these were marines, so on 
that basis they were not given primaquine. That decision was 
unfortunate in one respect and extremely fortunate in another. 
We had estimated that the malaria seed-rate in all returnees 
from Korea would be about 20%. Among the returned soldiers, 
about 280,000, the relapse rate following primaquine treat-
ment was close to nil. However, in the marines, most of whom 
went to Camp LeJuen, more than 19% came down with ma-
laria. The navy was embarrassed, but we were elated because 
the navy had unwittingly performed the crucial experiment 
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to prove that primaquine would cure infections of vivax 
malaria. 
We next turned our attention to a new type of anti-
malarial drug, produced by the Wellcome Laboratories in 
New York, known as pyrimethamine. Therapeutic studies in 
lower animals and the prisoner volunteers showed that it had 
the highest activity against blood forms of the parasite of 
any known antimalarial. One of the technicians in our NIH 
testing laboratory told me, with a twinkle in her eyes, that 
she was afraid to open a bottle of the drug in the laboratory 
for fear it would cure every infection in the room. However, 
resistance to pyrimethamine developed quickly against the 
blood infection in avian, simian, and human malaria; more 
disturbing was the fact that the resistance factor was trans-
mitted unchanged through the mosquito. Subsequent studies 
showed deleterious changes in the bone marrow and kidneys 
of man. It was an excellent drug whose disadvantages out-
weighed its usefulness. 
As a consultant to the Parke Davis Company, I made fre-
quent trips to their home plant and always made it a point to 
needle the chemists about their failure in developing a highly 
effective injectable drug that would give protection over an 
extended period. They seemed to shrug off that suggestion, 
but in the end they developed an effective drug known as 
Camolar. A single injection gave protection against a sporo-
zoite-induced malaria in volunteers for upwards of one year. 
Such results were unheard of in the management of malarial 
infections. On the basis of such extraordinary results, it was 
decided to test the drug in the field. At the invitation of the 
Government of Pakistan, Dr. Peter Contacos and I went there 
only to meet up with the problem of resistance to chlor-
guanide, the parent form of the drug. That coupled with the 
disadvantage of distress at the site of injection caused us to 
terminate the trials. Another case where many are called but 
few are chosen. 
I know at some time during this essay, time should be 
given for a more complete account of the volunteers and their 
contribution to the biology of the human malarias, to the 
search for new antimalarial drugs, and to their attitude toward 
participation. I shall do so now. 
Those men considered themselves the elite of the prison 
population and, in a sense, they were. They had been selected 
first by the custodial staff and select~tl again by our medical 
staff. As volunteers they were exempt from many of the 
prison rules. All their illnesses, except surgery, were handled 
by the project physicians, and they had the only wide-screen 
color TV in the prison. To project their elitest view they de-
signed their own patch with an embroidered MP (malaria 
project) in bright yellow on a blue denim background, which 
they sewed on their left sleeve above the elbow. 
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On our side, we instituted a series of strict routine pro-
cedures necessary for the scientific accuracy of the study and 
for 24-hour overall control of the project. The staff received 
relatively few complaints concerning these procedures, because 
the volunteers understood the need for them. A few objected 
and considered withdrawing from the study, which they had 
every right to do, but in so doing they would have to give up 
their good time, their elitest status, and withstand the scorn, 
or worse, of their project-mates where the maxim was: we are 
all in this together. Among approximately one thousand men, 
fewer than a handful withdrew. 
Administration of test drugs was decided by lot. This was 
fair and necessary because it prevented any semblance of 
favoritism by the staff. When a man drew a number, that was 
it. If a test drug was not effective, the volunteer would come 
down with the disease: high fever, etc. If effective, he would 
be protected. The same procedure was used when testing drugs 
for therapeutic effectiveness. The men saw this as "the luck of 
the draw." Once while interviewing a volunteer I asked him 
why he wanted to join the project. He replied, "I have a 
brother in the army and this is the only way I can fight." We 
took him. 
One day Dr. Cooper told me that "Jones" was having a 
tough time. I went to the ward to see him. He had just gone 
through a prolonged vomiting episode, and as I approached his 
bed he gave me a faint smile. I asked him how things were 
going. I will never forget his reply: "Doc, I wouldn't go through 
this again for a million dollars, but I'll go through with it this 
time if it kills me." I could only say, "Thank you. You're a 
real soldier." 
On another occasion I was awarding certificates to those 
who had completed their six-month participation. As one 
man's name was called, he stepped forward a couple of steps 
and asked if he could say something. I agreed and he said, 
"Please send that certificate to my mother. I don't want to 
touch it. It's the only honest thing I have ever done." That 
mother got the certificate and a letter from me praising her 
son's participation. 
I think I should include one more example for, to my 
mind, it gives the attitude of the volunteer as he saw it. The 
Parke Davis Company was considering setting up their own 
drug-testing facility in the Florida State Prison at Raiford. I 
was invited to go there as a consultant, and as I was walking 
along one of the hospital corridors an inmate, who was mop-
ping the floor, looked up and said, "Hi, Doc. Are you going to 
set up a malaria project here? If you are, I want on it." My 
reply was, "Thanks we may need you." That man had been a 
volunteer in our Atlanta prison project, received his good time, 
and was then serving time in Florida. He was a walking adver-
tisement for our volunteer program. 
Up to 1960 I had worked mainly in two fields: (1) the 
blood parasites of birds, including malaria; and (2) the biology 
and chemotherapy of the human malarias. Then came a de-
cided change. On 5 May I was sitting at my desk at the NIH 
when a call came through from Dr. Don Eyles, in charge of 
our Memphis laboratory, and I heard him say, "Bob, I have 
monkey malaria." I was incredulous. I told him not to take 
chloroquine until we were sure. He replied that he expected 
I would say that so he had taken the drug before he called. 
In other words, he was the one suffering the chills and fever-
not I. Prior to taking the drug, he had drawn 20 cc of his own 
blood and injected a portion of it into an uninfected monkey. 
I asked him to send the remainder to the Atlanta prison for 
transfer to volunteers. That was done, and in a few days the 
recipient monkey and each of the volunteers came down with 
malaria. Plasmodium cynomolgi of monkeys would grow in 
man and produce disease. Malariologists, including myself, 
knew that monkeys harbored malaria infections, but erron-
eously we thought malaria in the monkey was for monkeys 
and malaria in man was for people. That tenet would have to 
be discarded. The greater question was: is monkey malaria a 
true zoonosis, an anthroponosis, or both? 
At the time of the Eyles accidental infection by mosquito 
bite, three species of simian malaria were known from Malaya. 
The species responsible for his infection had been isolated from 
a monkey in northeastern Malaya. Under the circumstances 
it seemed worthwhile to go there to study the simian malarias. 
When I presented the opportunity to Eyles, he was enthusias-
tic and went there in August with a small staff. He had three 
main objectives: (1) to study malaria in the indigenous mon-
keys, (2) to determine their natural vectors, and (3) to inves-
tigate the possibility of the natural transmission of monkey 
malaria to man. 
The productivity of the Eyles group was phenomenal. 
During less than four years they identified two dozen vectors 
of simian malaria and described five new species (one was 
named for me). When those are added to the three already 
known, Malaya is surely the birthplace of malaria and, I like 
to think, maybe the Biblical Garden of Eden. Dr. Eyles's 
untimely death cut short a brilliant career and eventually reo 
sulted in our closing the laboratory. 
The simian malaria program at the Atlanta prison was in. 
the charge of Dr. Peter Contacos, and as the Malayan and other 
species of simian malaria became available they were sent to 
him for possible transfer to prison volunteers. Con tacos estab-
lished five simian species in man and carefully described their 
parasitology and clinical manifestations in studies involving 
some 225 volunteers. 
At this juncture I had spent some twenty years in charge 
of studies involving human and simian malarias, their biology, 
and treatment. The human hosts for these studies were prison 
volunteers, as mentioned earlier, who willingly accepted the 
rigors of the disease and the uncertainty of the test drugs. Their 
antisocial conduct had landed these men behind bars, but they 
proved to have honor too. If they made a commitment, they 
kept it. I can certify that the PHS kept its commitment to 
them. I was privileged to work with these men longer than any 
staff member. It was an experience of a lifetime, and I cherish 
the opportunity. 
Most of what I have dealt with here has had to do with 
the evaluation of new drugs in man and with the possible 
threat of simian malaria as a zoonosis, but I am not unmindful 
of the work carried on in our laboratories at the NIH, Colum-
bia, South Carolina, and Memphis, Tennessee, in support of 
those studies: the initial testing of potentially effective drugs 
against blood- and sporozoite-induced P. gallinaceum infections 
in day-old chicks, a program that embraced more than 2,000 
compounds; the intensive study of all aspects of P. gallanaceum 
infections in young chicks; Miss Helen Trembly's management 
of the insectary where countless thousands of mosquitoes 
were raised for transmission of malarias to the chicks and to 
humans; the basic studies on drug metabolism by Drs. Howard 
Bond and John Sherman; Dr. Joseph Greenberg's discovery of 
synergism in antimalarials; and Dr. Joe Held's technique for 
locating malarial exoerythrocytic bodies in the liver of infected 
monkeys. These highlights, plus others too numerous to men-
tion, came about with me, in terms of the game of football, as 
coach and quarterback. However, let it not be forgotten that it 
was the members of a remarkable staff who carried the ball. My 
philosophy was, and is, that team research hinges on finding 
someone else to do what I want done because he wants to do it. 
In 1960 I was named chief of the Laboratory of Parasite 
Chemotherapy and continued in that capacity until terminated 
by the law that states that commissioned officers of the PHS 
must retire at age 64. Tempus vitam regit. As a consequence, 
Captain Coatney became a civilian following his retirement on 
31 May 1966. 
t t t 
Epilogue 
Prior to my retirement I had been invited to accept a 
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position as Professor of Pharmacology at the Louisiana State 
University School of Medicine in New Orleans and had 
accepted. My teaching schedule allowed ample time for re-
search, and upon inquiry I learned that several chimpanzees at 
the Delta Regional Primate Center, at nearby Covington, 
Louisiana, were available for studies involving malaria. The 
availability of these animals gave an opportunity to study 
Plasmodium schwe tzi, an ape parasite, which had eluded us 
earlier. Through a series of fortunate circumstances two 
chimps were infected by the inoculation of infected blood 
and, in due time, through the cooperation of Dr. Contacos, 
then in charge of myoid Atlanta project, prisoner volunteers 
were infected through the bites of infected mosquitoes. The 
malaria parasite which infected the volunteers was not like P. 
schwetzi, as expected, but like P. ovale which we knew quite 
well as a tertian malaria parasite of man. When the parasite 
was transferred back to an uninfected chimpanzee the result-
ing infection was P. schwetzi again. At that point I decided 
to let some other investigator unravel the P. schwetzi-P. ovale 
riddle. Those confusing results remind us that when we ask 
questions of nature the answer may be pleasant, shocking, or 
wrapped in an enigma. 
After three enjoyable and scientifically profitable years in 
New Orleans, I decided to retire a second time. We moved to 
Atlanta, Georgia, a beautiful city with a mild climate, many 
old friends, and former colleagues. 
During a luncheon with a group of former staff mem-
bers, the question was raised about finishing the book on 
the primate malarias begun in 1966 and abandoned. Drs. 
William Collins, McWilson Warren, and Peter Contacos agreed 
to collaborate if I would assume overall responsibility. We 
all got to work and The Primate Malarias appeared in 1971. 
Our aim was to present a comprehensive treatment of all the 
primate malarias. If that aim was realized, and I think it was, 
it is an important addition to the literature of the primate 
malarias. 
Now I am a true retiree-mowing the lawn, getting 
reacquainted with my malaria-related stamp collection, and 
enjoying an introduction to historical horology to the extent 
of collecting and writing about early American clocks. Retire-
ment is wonderful if one can get used to it. 
